coin-img-ETHETH-0.20%coin-img-BTCBTC-0.90%coin-img-SOLSOL-0.71%coin-img-USDCUSDC-0.01%coin-img-XRPXRP-0.51%coin-img-FLYAIFLYAI+4,699.92%coin-img-HYPEHYPE-3.18%coin-img-TRXTRX-0.06%coin-img-ETHETH-0.20%coin-img-BTCBTC-0.90%coin-img-SOLSOL-0.71%coin-img-USDCUSDC-0.01%coin-img-XRPXRP-0.51%coin-img-FLYAIFLYAI+4,699.92%coin-img-HYPEHYPE-3.18%coin-img-TRXTRX-0.06%coin-img-ETHETH-0.20%coin-img-BTCBTC-0.90%coin-img-SOLSOL-0.71%coin-img-USDCUSDC-0.01%coin-img-XRPXRP-0.51%coin-img-FLYAIFLYAI+4,699.92%coin-img-HYPEHYPE-3.18%coin-img-TRXTRX-0.06%coin-img-ETHETH-0.20%coin-img-BTCBTC-0.90%coin-img-SOLSOL-0.71%coin-img-USDCUSDC-0.01%coin-img-XRPXRP-0.51%coin-img-FLYAIFLYAI+4,699.92%coin-img-HYPEHYPE-3.18%coin-img-TRXTRX-0.06%
user-avatar
The Manila Times

Samsung Biologics posts Q2 2026 record results with KRW 1,321 billion revenue, KRW 586 billion operating profit

Samsung Biologics (KRX: 207940.KS) reported record second-quarter 2026 revenue of KRW 1,321 billion and operating profit of KRW 586 billion, and said cumulative contract value for the first half reached USD 21.6 billion. The company said Plant 5’s Process Performance Qualification (PPQ) work accelerated, while its all-cash public tender offer for PolyPeptide Group is expected to be completed toward the end of 2026. Samsung Biologics reiterated it remains on track to achieve the upper end of its previously announced 2026 guidance. The company said the results reflect sustained strength in its CDMO business and execution of global expansion plans.
Disclaimer: The content above is only the author's opinion and does not represent BingX’s stance. It shall not be construed as investment advice from BingX. For details, refer to the Terms and Conditions.
Stocks

Risk Warning

Cryptocurrencies and their derivatives are innovative financial products with great volatility and high investment risks.

Although BingX is committed to providing users with easy-to-use trading tools, trading itself is still a highly sophisticated field. Trading digital assets and their derivatives are subject to high market risk and price volatility and may result in partial or total loss of account funds. You must carefully consider and exercise clear judgment to evaluate your financial situation and the aforementioned risks before using BingX Services. You shall be responsible for all losses arising therefrom. If necessary, please consult relevant professionals to make informed decisions before investing. By accessing, downloading, using or clicking on "I agree" to accept any BingX Services provided by BingX, you agree that you have read, understood and accepted all of the terms and conditions stipulated in BingX Terms of Use as well as our Privacy Policy.


Trading by copying or replicating the trades of other traders involves a high level of risks, even when copying or replicating the top-performing traders. Past performance of a BingX community member is not a reliable indicator of his future performance. Content on BingX's trading platform is generated by members of its community and does not contain advice or recommendations by or on behalf of BingX.